Amended Current Report Filing (8-k/a)
September 19 2016 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): _____
August 23, 2016
______
NORTHWEST BIOTHERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-35737
|
94-3306718
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite
800
Bethesda, MD 20814
|
(Address of principal executive offices)
|
(204) 497-9024
|
(Registrant’s telephone number, including area code)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Explanatory Note
: As
previously indicated,
Northwest
Biotherapeutics, Inc. (the “Company”) is now amending the Current Report on Form 8-K filed on August 23, 2016
(the “Original Current Report”) for the sole purpose of including the Exhibits referenced in the Original Current
Report and disclosing non-material revisions to the number of warrants exercised by the Holders, as that term is defined
therein, as well as the gross proceeds thereof, and the number of Series E Common Stock Purchase Warrants issued to the
Holders.
As previously reported,
on August 23, 2016, the Company entered into agreements with certain holders (the “Holders”) of warrants exercisable
for Common Stock of the Company, pursuant to which agreements the Holders exercised warrants to purchase 3,656,817 shares of Common
Stock at $0.35 per share for gross proceeds of approximately $1,279,885, and the Company issued new Series E Common Stock Purchase
Warrants exercisable for up to 3,656,817 shares of Common Stock at an exercise price of $0.41 per share. Subsequently, the Holders
exercised warrants to purchase 3,758,880 shares of Common Stock for gross proceeds of approximately $1,315,608 and were issued
Series E Common Stock Purchase Warrants to purchase up to 3,758,880 shares of Common Stock.
Item 9.01.
|
Financial Statements and Exhibits .
|
Exhibit
Number
|
|
Description
|
|
|
|
10.1
|
|
Form of Letter Purchase Agreement dated August 23, 2016 by and between Northwest Biotherapeutics, Inc. and certain purchasers
|
|
|
|
10.2
|
|
Form of Series E Common Stock Purchase Warrant
|
|
|
|
10.3
|
|
Form of Registration Rights Agreement
|
|
|
|
10.4
|
|
Engagement Agreement, dated August 19, 2016 by and between Northwest Biotherapeutics, Inc. and H.C. Wainwright & Co., LLC, as placement agent
|
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
Date: September 16, 2016
|
By:
|
/s/
Linda F. Powers
|
|
|
Name: Linda F. Powers
|
|
|
Title: Chief Executive Officer
|
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jul 2023 to Jul 2024